Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 953 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06412120RecruitingPhase 4
Niraparib safety and metabolism study in Black women
This trial tests a new maintenance therapy called niraparib for Black women who have finished initial treatment for advanced ovarian cancer and are in remission or partial response. It aims to see if the drug is safe and how your body processes it.
Fort Lauderdale, FloridaAges 18 years+ - NCT07684235RecruitingPhase 3
Long-term study of a weight-loss drug for trial graduates
This study tests a drug called Maridebart Cafraglutide for long-term weight management in people who completed a previous related trial. It looks at how well the drug works and its safety over time.
Daphne, AlabamaAges 18–99 - NCT07736638RecruitingPhase 1
Testing safety and tolerability of ABBV-859 in healthy adults
This trial studies a new drug called ABBV-859 in healthy volunteers to see how safe it is and how the body processes it. It helps doctors decide the right dose for future studies.
Anaheim, CaliforniaAges 18–65 - NCT07179640RecruitingPhase 1/Phase 2
Testing ALE1 for hypophosphatasia in healthy people and patients
This trial tests a new medicine called ALE1 for hypophosphatasia (HPP), a rare bone condition. It first checks safety in healthy volunteers, then tests if the medicine helps people with HPP.
WürzburgAges 18–50 - NCT07217067RecruitingPhase 2
Study of PKN605 for people with atrial fibrillation
This trial tests a new medicine called PKN605 for people with atrial fibrillation (irregular heartbeat). The goal is to see if it can safely help control heart rhythm. You will need to have had at least two AF episodes recently and meet other heart health criteria.
Tupelo, MississippiAges 18 years+ - NCT07483827RecruitingPhase 1
Testing CPV-104 safety in healthy people and C3G patients
This trial tests a new drug called CPV-104. First, healthy volunteers will receive a single dose to check safety. Then, people with C3 glomerulopathy (a rare kidney disease) will receive multiple doses to see if it helps and is safe.
ViennaAges 18 years+ - NCT06596681RecruitingEarly Phase 1
Study of GA for hard-to-treat nerve pain
This early-phase trial tests a new treatment called GA for people with hard-to-treat neuropathic pain that hasn't improved with standard therapies. The goal is to see if it is safe and tolerable.
Beijing, Beijing MunicipalityAges 18–65 - NCT07525960RecruitingPhase 1
Testing NDI-5001 for X-linked Nephrogenic Diabetes Insipidus
This study tests a new drug called NDI-5001 in adult men with a specific genetic form of nephrogenic diabetes insipidus (a condition where the kidneys cannot concentrate urine properly). The trial checks whether the drug is safe, how your body handles it, and whether it might help reduce excessive urination and thirst.
Jacksonville, FloridaAges 18–55 - NCT07419841RecruitingPhase 1
A study of CTX-10726 for certain advanced cancers
This trial tests a new drug called CTX-10726 in people with advanced kidney, liver, stomach, or uterine cancer that has not responded to standard treatments. The goal is to see if the drug is safe and tolerable.
Omaha, NebraskaAges 18 years+ - NCT05759923RecruitingPhase 1
Study of OATD-02 for hard-to-treat solid tumors
This early (first-in-human) study tests whether OATD-02 is safe and tolerable, and whether it shows any anti-cancer activity. It is for adults with certain advanced or metastatic cancers that have already been treated with the standard options.
Bydgoszcz, Kuyavian-Pomeranian VoivodeshipAges 18 years+ - NCT07734623Recruiting
Ultrasound treatment for severe opioid or amphetamine use disorder
This trial tests a low-intensity focused ultrasound treatment for people with severe opioid or amphetamine use disorder. The ultrasound targets a part of the brain linked to addiction, and the goal is to see if it is safe and helpful.
TaipeiAges 20–50 - NCT07559136RecruitingPhase 1
Safety study of HRS9531 injection for teen obesity
This study tests whether a new injectable medication called HRS9531 is safe and well-tolerated in teenagers aged 12–17 with obesity. Researchers will monitor how your body handles the medication and whether it affects your weight.
Wuhan, HubeiAges 12–18 - NCT07652242RecruitingPhase 1
A RNA vaccine for stage 2-3 triple negative breast cancer
This trial tests an experimental RNA vaccine (ITI-5000) designed to help your immune system fight triple-negative breast cancer. It is for people with stage 2 or 3 disease who have already had some cancer treatment.
Grand Rapids, MichiganAges 18 years+ - NCT07517263RecruitingPhase 3
Long-term Safety Study of Pelacarsen Treatment
This study follows patients who completed an earlier pelacarsen trial to check if the treatment remains safe and well-tolerated over time. Pelacarsen is an experimental medicine being tested for heart and cholesterol health.
Andalusia, AlabamaAges 18–100 - NCT06744920RecruitingPhase 3
New drug for generalized myasthenia gravis
This trial tests a new medication (remibrutinib) versus a placebo to see if it helps adults with generalized myasthenia gravis. You may qualify if your symptoms affect multiple parts of your body and you haven't had certain recent treatments.
Phoenix, ArizonaAges 18–85 - NCT07140614RecruitingPhase 1
Study of EDK060 for adults with CMT1A
This trial tests a new medicine called EDK060 for people with Charcot-Marie-Tooth disease type 1A (CMT1A). The study will check if the drug is safe and how the body processes it, with the goal of finding better treatments for this condition.
Ottawa, OntarioAges 18–60 - NCT07234942RecruitingPhase 1
Safety study of RO7812653 for early Alzheimer's disease
This trial tests a new drug, RO7812653, in people with early symptomatic Alzheimer's disease (including mild cognitive impairment due to AD). The goal is to see if it is safe and how the body handles it.
Toronto, OntarioAges 50–75 - NCT07201558RecruitingPhase 1
Surovatamig safety study for rheumatoid arthritis or lupus
This trial tests surovatamig, a new experimental treatment, to see if it's safe and how the body processes it in adults with moderate-to-severe rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). It may be an option if you've tried other biologic or targeted therapies without success.
Birmingham, AlabamaAges 18–65 - NCT07467993RecruitingPhase 2
Testing GXV813 for hospitalized adults with schizophrenia
This trial tests a new drug, GXV813, to see if it helps reduce symptoms in people with schizophrenia who are currently hospitalized due to a sudden worsening of their condition. It compares the drug's safety and effect against a placebo over several weeks.
Bentonville, ArkansasAges 18–65 - NCT07702890RecruitingPhase 1/Phase 2
Testing a new drug for obesity and type 2 diabetes
This trial tests an investigational drug called GUB-UCN2 in people who are healthy, overweight, or have type 2 diabetes. The goal is to see if the drug is safe and how the body processes it.
NeussAges 18–75 - NCT07704840RecruitingPhase 2
Testing a new pill for post-stroke arm stiffness
This study tests an experimental pill (BMS-986368) that targets two brain chemicals to reduce muscle stiffness after a stroke. It's for people who had a stroke in the last 4 to 18 months and have moderate tightness in their elbow and wrist.
Elkins Park, PennsylvaniaAges 18–80 - NCT07266402RecruitingPhase 3
Study of barzolvolimab for cold hives or skin writing
This trial tests an investigational drug called barzolvolimab for people with cold-induced hives or a condition where scratching causes raised lines (symptomatic dermographism) that aren't well controlled by antihistamines. The study compares the drug to a placebo to see if it reduces itching and hives.
Birmingham, AlabamaAges 18 years+ - NCT07321106RecruitingPhase 1
CBI-1214 for advanced colorectal cancer
This trial tests a new drug called CBI-1214, which is designed to help your immune system attack cancer cells. It is for people with advanced colorectal cancer that has not responded to other treatments.
Phoenix, ArizonaAges 18 years+ - NCT07682896RecruitingPhase 2
Testing YB-101 for safety and effectiveness in Graves' disease
This trial tests an investigational drug called YB-101 for people with Graves' disease, whether or not they have thyroid eye disease. The goal is to see if the drug is safe and can help.
Gilbert, ArizonaAges 18 years+
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 953 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.